EGFR
Les inhibiteurs du récepteur du facteur de croissance épidermique (EGFR) sont des composés qui bloquent la signalisation de l'EGFR, un récepteur souvent surexprimé dans divers cancers et qui joue un rôle crucial dans l'angiogenèse. Les inhibiteurs de l'EGFR sont utilisés pour prévenir la croissance tumorale et les métastases en perturbant les voies qui favorisent la formation de vaisseaux sanguins dans les tumeurs. Ces inhibiteurs sont largement utilisés dans la recherche et le traitement du cancer. Chez CymitQuimica, nous offrons une sélection diversifiée d'inhibiteurs de l'EGFR de haute qualité pour soutenir vos recherches en oncologie et angiogenèse.
609 produits trouvés pour "EGFR".
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
DS06652923
DS06652923 is an orally active inhibitor targeting EGFR triple mutations. It exhibits growth-inhibitory effects on Ba/F3EGFRdel19/T90M/C795S cells, with a GI50 value of 9.4 nM. Additionally, DS06652923 induces tumor regression in the Ba/F3 syngeneic transplantation model.Couleur et forme :Odour SolidSJF 1528
CAS :SJF 1528 is an EGFR PROTAC degrader (WT DC50=39.2 nM) that induces EGFR/HER2 degradation for breast cancer research.Formule :C55H57ClFN7O8SCouleur et forme :SolidMasse moléculaire :1030.61EGFR-TK-IN-5
EGFR-TK-IN-5 (Compound NCE 2) is a thiazolyl pyrazoline derivative with significant inhibitory activity and stability against EGFR. It is applicable in tumor research.Formule :C26H20ClFN4OSCouleur et forme :SolidMasse moléculaire :490.98MS9449
CAS :MS9449 is a powerful EGFR PROTAC; Kd: 17 nM (WT), 10 nM (L858R); targets mutant EGFRs via UPS and autophagy; hinders NSCLC cell growth.Formule :C60H76ClFN10O8SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1151.82Matuzumab
CAS :Matuzumab (EMD 72000) is a humanized monoclonal antibody targeting EGFR that can be used to study non-small cell lung cancer.Degré de pureté :95%Couleur et forme :LiquidMasse moléculaire :145.9 kDaPROTAC EGFR degrader 11
CAS :PROTAC EGFR degrader 11 (Compound B71) is a PROTAC degrader targeting the epidermal growth factor receptor (EGFR), with a DC50 of less than 100 nM. It binds to CRBN-DDB1 with a Ki of 36 nM. This compound effectively degrades EGFR, focal adhesion kinase (FAK), and RSK1, and inhibits the proliferation of BaF3 wild-type and EGFR mutant cells, exhibiting an IC50 of less than 100 nM.Formule :C49H64ClFN10O7SCouleur et forme :SolidMasse moléculaire :991.61BMS-599626
CAS :BMS-599626 (AC480) has been used in trials studying the treatment of Cancer, Metastases, and HER2 or EGFR Expressing Advanced Solid Malignancies.Formule :C27H27FN8O3Degré de pureté :98.73%Couleur et forme :SolidMasse moléculaire :530.55DP-C-4
DP-C-4 is a Cereblon-based dual PROTAC for simultaneous degradation of EGFR and PARP[1].Couleur et forme :SolidJBJ-09-063
CAS :JBJ-09-063: EGFR inhibitor, IC50s 0.147-0.396 nM for various mutants; hinders EGFR/Akt/ERK1/2 phosphorylation; targets TKI-sensitive/resistant lung cancer.Formule :C31H29FN4O3SCouleur et forme :SolidMasse moléculaire :556.65Varlitinib
CAS :Varlitinib (ASLAN001) is a potent, reversible, small molecule pan-EGFR inhibitor with IC50s of 7, 2, 4 nM for HER1, HER2 and HER4, respectively.Formule :C22H19ClN6O2SDegré de pureté :99.51%Couleur et forme :SolidMasse moléculaire :466.94OK2
OK2, a specific inhibitor of the CCN2/EGFR interaction, effectively disrupts this interaction by binding to the CT domain of CCN2.Formule :C42H62N14O9Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :907.03JBJ-09-063 TFA
JBJ-09-063 TFA, an EGFR inhibitor selective for EGFR mutations, IC50s: 0.147-0.396 nM, blocks EGFR/Akt/ERK signaling, for EGFR-mutant lung cancer research.Formule :C33H30F4N4O5SCouleur et forme :SolidMasse moléculaire :670.67HER2-IN-13
CAS :HER2-IN-13 (Compound 33) serves as an effective HER2 inhibitor, exhibiting an IC50 value of 8 nM, and additionally demonstrates inhibition of wt-EGFR with anFormule :C26H23ClF2N8O3Couleur et forme :SolidMasse moléculaire :568.96BMS-599626 2HCL
CAS :BMS-599626 2HCL (AC480 2HCl) is a BMS-599626 derivative.Formule :C27H29Cl2FN8O3Degré de pureté :99.11%Couleur et forme :Odour SolidMasse moléculaire :603.47ErbB-2-binding peptide
CAS :ErbB-2-binding peptide (HER2-binding peptide), a tumor-targeting peptide, holds potential for cancer research applications [1].Formule :C43H60N8O11Couleur et forme :SolidMasse moléculaire :864.98MC-Val-Cit-PAB-Amide-TLR7 agonist 4
CAS :MC-Val-Cit-PAB-Amide-TLR7 agonist 4 Conjugate is a conjugate formed by linking MC-Val-Cit-PAB-Amide and TLR7 agonist 4, useful for cancer research.Formule :C52H72N12O11Degré de pureté :97.70%Couleur et forme :White SolidMasse moléculaire :1041.2EGFR-IN-43
EGFR-IN-43 (17c) is a potent EGFR inhibitor with ER antagonist action, tamoxifen/endoxifen+gefitinib linkage, and strong anticancer activity.Formule :C50H55ClFN5O5Couleur et forme :SolidMasse moléculaire :860.45EGFR-IN-15
CAS :EGFR-IN-15 (compound I-005) is a potent EGFR inhibitor, exhibiting an IC50 value of 4 nM. This compound holds potential for oncological research applications.Formule :C24H25BrN6O2Couleur et forme :SolidMasse moléculaire :509.408HER2-IN-18
HER2-IN-18 is an HER2 inhibitor with an IC50 of less than 200 nM for both HER-YVMA and HER-WT. This compound is applicable in cancer research.Formule :C26H24N8O2Couleur et forme :SolidMasse moléculaire :480.20222EGFR-IN-42
EGFR-IN-42 (17b) is a potent EGFR inhibitor with nanomolar efficacy, merging tamoxifen/endoxifen and gefitinib, exhibiting enhanced anti-cancer action.Formule :C49H53ClFN5O5Couleur et forme :SolidMasse moléculaire :846.43
